Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $509.83M. Across the group, the median move over the past trading day is +0.06%. Price change over the past year runs from −73.4% to +446.2% across the middle 80 percent of the group, with a median of +3.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc. | $37.00 | +15.70% | +54.88% | +45.50% |
| IMMX | Immix Biopharma, Inc. | $14.07 | +66.71% | +159.12% | +617.86% |
| BCDA | BioCardia, Inc. | $1.19 | +52.56% | −6.30% | −38.66% |
| FBLG | FibroBiologics, Inc. | $1.41 | +116.92% | −70.62% | −88.25% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.